Distribution system and method for determining multiple types of cancer - Patents.com
An aqueous two-phase partition system with tailored solvent properties differentiates between cancer types by analyzing protein partition behavior, addressing the limitation of existing systems in distinguishing between various cancer types.
Patent Information
- Application Number
- JP2024525959
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-28
- Filing Date
- 2022-10-13
- Publication Date
- 2024-11-13
AI Technical Summary
Existing aqueous partition systems are effective for distinguishing between cancerous and non-cancerous conditions but lack the ability to differentiate between various types of cancer based on structural modifications in proteins.
An aqueous two-phase partition system is developed with specific solvent properties, including differences in polarity/polarizability, hydrogen bond donor acidity, hydrogen bond acceptor basicity, and electrostatic properties, allowing for the differentiation of different cancer types by analyzing the partition behavior of proteins.
The system effectively distinguishes between various cancer types by sensitively detecting structural changes in proteins, providing a diagnostic tool for cancer differentiation.
Smart Images

Figure 2024542059000001 
Figure 2024542059000002 
Figure 2024542059000003
Abstract
Description
[Technical field]
[0001] (Related Applications) This application claims the benefit of U.S. Provisional Patent Application No. 63 / 272,759, entitled "Partitioning Systems and Methods for Determining Multiple Types of Cancers," filed October 28, 2021, which is incorporated by reference in its entirety.
[0002] (Field) The present disclosure relates generally to systems and methods for distributing seeds. In some embodiments, such systems may be used to determine one or more types of cancer. [Background technology]
[0003] (background) Aqueous partitioning systems are generally known to be sensitive to structural changes in small molecules, proteins, viruses, etc. See, for example, U.S. Patent Nos. 7,968,350; 8,099,242; 8,211,714; or 9,354,229 (each of which is incorporated herein by reference in its entirety). These partitioning systems can be used, for example, to detect structural modifications by proteins (e.g., produced by cancer cells). For example, cancers can alter such proteins by alternative splicing, conformational changes, post-translational modifications (especially specific glycosylation), protein-protein interactions, etc. Thus, such aqueous partitioning systems have been used previously to distinguish between cancer and non-cancerous conditions. However, partitioning systems for distinguishing between various types of cancer have not been described previously. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] U.S. Patent No. 7,968,350 [Patent Document 2] U.S. Pat. No. 8,099,242 [Patent Document 3] U.S. Pat. No. 8,211,714 [Patent Document 4] U.S. Pat. No. 9,354,229 Summary of the Invention [Means for solving the problem]
[0005] (overview) The present disclosure generally relates to a system and method for distributing seeds. In some embodiments, such a system can be used to determine one or more types of cancer. The subject matter of the present disclosure in some cases involves interrelated products, alternative solutions to a particular problem, and / or multiple different uses of one or more systems and / or articles.
[0006] In one embodiment, the composition generally comprises an aqueous two-phase partitioning system having a first phase and a second phase, Aqueous two-phase partitioning systems include: (i) The difference in solvent dipolarity / polarizability (Δπ * ) where Δπ * is the dipolarity / polarizability of the first phase (π * ) and the dipolarity / polarizability of the second phase (π * ), and π * is the wave number (ν1) of the longest wavelength absorption band of 4-nitroanisole in each phase in cm -1 Measure in units of π in each phase * the difference in solvent dipolarity / polarizability, determined separately in each phase by calculating as 0.427(34.12-ν1); (ii) a difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of 0.001 + / - 0.035, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of the carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932)[(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating as: (iii) a difference in the hydrogen bond acceptor basicity (Δβ) of the solvent between the first and second phases of −0.050±0.021, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν) of the longest wavelength absorption band of 4-nitrophenol in each phase in cm -1 The units are 0.346(35.045-ν2)-0.57π, and the β in each phase is 0.346(35.045-ν2)-0.57π. * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between the first and second phases of 0.020 + / - 0.135, c being determined by separately partitioning each dinitrophenylated amino acid sodium salt of Table I in an aqueous two-phase partitioning system, determining the partition coefficient (K) of each sodium salt, and calculating the partition coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I. c ) to log 10 K=c+EN c The difference in electrostatic properties is determined by regressing having Table I shows [Table 1-1] The present invention is directed to a composition,
[0007] Another aspect generally relates to a composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, Aqueous two-phase partitioning systems include: (i) The difference in dipolarity / polarizability of the solvent between the first and second phases (Δπ * ) where Δπ * is the dipolarity / polarizability of the first phase (π * ) and the dipolarity / polarizability of the second phase (π * ), and π * is the wave number (ν1) of the longest wavelength absorption band of 4-nitroanisole in each phase in cm -1 Measure in units of π in each phase * the difference in solvent dipolarity / polarizability, determined separately in each phase by calculating as 0.427(34.12-ν1); (ii) the difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase selected from a row in Table II, Δα being determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, α being determined by measuring the maximum wavelength (λ) of the absorption band of the carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932)[(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating as: (iii) The difference in hydrogen bond acceptor basicity (Δβ) of the solvent between a first phase and a second phase selected from a row in Table II, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν) of the longest wavelength absorption band of 4-nitrophenol in each phase, expressed in cm -1 The units are 0.346(35.045-ν2)-0.57π, and the β in each phase is 0.346(35.045-ν2)-0.57π. *the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between a first phase and a second phase selected from a row in Table II, c being determined by separately distributing each of the dinitrophenylated amino acid sodium salts of Table I in an aqueous two-phase partitioning system, determining the partition coefficient (K) of each, and calculating the partition coefficient (K) and the methylene equivalent (N) of each of the dinitrophenylated amino acid sodium salts of Table I. c ) to log 10 K=c+EN c The difference in electrostatic properties is determined by regressing having Table I shows [Table 1-2] and Table II [Table 2-1] The present invention is directed to a composition,
[0008] Yet another aspect generally relates to a composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, Aqueous two-phase partitioning systems include: (i) The difference in dipolarity / polarizability of the solvent between the first and second phases (Δπ * ); (ii) the difference in hydrogen bond donor acidity of the solvent between the first and second phases (Δα), selected from a row in Table II; (iii) the difference in hydrogen bond acceptor basicity of the solvent between the first phase and the second phase (Δβ), selected from a row in Table II; and (iv) a difference in electrostatic properties between the first phase and the second phase selected from a row in Table II (c) having Table II shows [Table 2-2] The present invention is directed to a composition,
[0009] Yet another aspect is generally directed to a composition comprising an aqueous multi-phase partitioning system exhibiting a first partition coefficient for a solute originating from a subject having a first type of cancer, a second partition coefficient for a solute originating from a subject having a second type of cancer, and a third partition coefficient for a solute originating from a subject having neither the first type of cancer nor the second type of cancer.
[0010] Yet another aspect generally relates to a composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, Aqueous two-phase partitioning systems include: (i) A difference in solvent dipolarity / polarizability (Δπ * ) where Δπ * is the dipolarity / polarizability of the first phase (π * ) and the dipolarity / polarizability of the second phase (π * ), and π * is the wave number (ν1) of the longest wavelength absorption band of 4-nitroanisole in each phase in cm -1 Measure in units of π in each phase * the difference in solvent dipolarity / polarizability, determined separately in each phase by calculating as 0.427(34.12-ν1); (ii) A difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of −0.380±0.095, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of the carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932)[(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating as: (iii) a difference in the hydrogen bond acceptor basicity (Δβ) of the solvent between the first and second phases of −0.020±0.019, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν) of the longest wavelength absorption band of 4-nitrophenol in each phase in cm -1 The units are 0.346(35.045-ν2)-0.57π, and the β in each phase is 0.346(35.045-ν2)-0.57π. * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between the first and second phases of 0.295 + / - 0.184, c being determined by separately distributing each of the dinitrophenylated amino acid sodium salts of Table I in an aqueous two-phase partitioning system, determining the partition coefficient (K) of each sodium, and calculating the distribution coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I. c ) to log 10 K=c+EN c The difference in electrostatic properties is determined by regressing having Table I shows [Table 1-3] The present invention is directed to a composition,
[0011] Another aspect generally relates to a composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, Aqueous two-phase partitioning systems include: (i) The difference in solvent dipolarity / polarizability (Δπ * ) where Δπ * is the dipolarity / polarizability of the first phase (π * ) and the dipolarity / polarizability of the second phase (π * ), and π * is the wave number (ν1) of the longest wavelength absorption band of 4-nitroanisole in each phase in cm -1 Measure in units of π in each phase *the difference in solvent dipolarity / polarizability, determined separately in each phase by calculating as 0.427(34.12-ν1); (ii) The difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of −0.183±0.048, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of the carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932)[(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating as: (iii) a difference in the hydrogen bond acceptor basicity (Δβ) of the solvent between the first and second phases of 0.060 + / - 0.020, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν) of the longest wavelength absorption band of 4-nitrophenol in each phase in cm -1 The units are 0.346(35.045-ν2)-0.57π, and the β in each phase is 0.346(35.045-ν2)-0.57π. * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between the first and second phases of 0.575 + / - 0.125, c being determined by separately partitioning each dinitrophenylated amino acid sodium salt of Table I in an aqueous two-phase partitioning system, determining the partition coefficient (K) of each sodium salt, and calculating the partition coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I. c ) to log 10 K=c+EN c The difference in electrostatic properties is determined by regressing having Table I shows [Table 1-4] The present invention is directed to a composition,
[0012] Yet another aspect generally relates to a composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, Aqueous two-phase partitioning systems include: (i) -0.040 + / - 0.040 Difference in dipolarity / polarizability of the solvent between the first and second phases (Δπ * ) where Δπ * is the dipolarity / polarizability of the first phase (π * ) and the dipolarity / polarizability of the second phase (π * ), and π * is the wave number (ν1) of the longest wavelength absorption band of 4-nitroanisole in each phase in cm -1 Measure in units of π in each phase * the difference in solvent dipolarity / polarizability, determined separately in each phase by calculating as 0.427(34.12-ν1); (ii) A difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of −0.270±0.052, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of the carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932)[(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating as: (iii) a difference in the hydrogen bond acceptor basicity (Δβ) of the solvent between the first and second phases of 0.021 + / - 0.022, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν) of the longest wavelength absorption band of 4-nitrophenol in each phase in cm -1The units are 0.346(35.045-ν2)-0.57π, and the β in each phase is 0.346(35.045-ν2)-0.57π. * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between the first and second phases of 0.050 + / - 0.060, c being determined by separately partitioning each dinitrophenylated amino acid sodium salt of Table I in an aqueous two-phase partitioning system, determining the partition coefficient (K) of each sodium salt, and calculating the partition coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I. c ) to log 10 K=c+EN c The difference in electrostatic properties is determined by regressing having Table I shows [Table 1-5] The present invention is directed to a composition,
[0013] Yet another aspect generally relates to a composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, Aqueous two-phase partitioning systems include: (i) The difference in solvent dipolarity / polarizability (Δπ * ) where Δπ * is the dipolarity / polarizability of the first phase (π * ) and the dipolarity / polarizability of the second phase (π * ), and π * is the wave number (ν1) of the longest wavelength absorption band of 4-nitroanisole in each phase in cm -1 Measure in units of π in each phase * the difference in solvent dipolarity / polarizability, determined separately in each phase by calculating as 0.427(34.12-ν1); (ii) A difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of −0.088±0.050, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of the carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932)[(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating as: (iii) a difference in the hydrogen bond acceptor basicity (Δβ) of the solvent between the first phase and the second phase of 0.102 + / - 0.023, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν) of the longest wavelength absorption band of 4-nitrophenol in each phase in cm -1 The units are 0.346(35.045-ν2)-0.57π, and the β in each phase is 0.346(35.045-ν2)-0.57π. * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between the first and second phases of 0.775 + / - 0.125, c being determined by separately partitioning each dinitrophenylated amino acid sodium salt of Table I in an aqueous two-phase partitioning system, determining the partition coefficient (K) of each sodium salt, and calculating the partition coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I. c ) to log 10 K=c+EN c The difference in electrostatic properties is determined by regressing having Table I shows [Table 1-6] The present invention is directed to a composition,
[0014] Another embodiment generally relates to a method including providing at least a first aqueous multi-phase partitioning system and a second aqueous multi-phase partitioning system substantially identical in composition to the first partitioning system; determining a first cancer in a first subject by adding a first sample from a first cancer subject to the first partitioning system and determining the partitioning of solutes in the first sample within the first partitioning system; and determining a second cancer in a second subject by adding a second sample from a second cancer subject to the second partitioning system and determining the partitioning of solutes in the second sample within the second partitioning system.
[0015] In another aspect, the disclosure includes methods of making one or more of the embodiments described herein (e.g., the aqueous distribution system). In yet another aspect, the disclosure includes methods of using one or more of the embodiments described herein (e.g., the aqueous distribution system).
[0016] Other advantages and novel features of the present disclosure will become apparent from the following detailed description of various non-limiting embodiments of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] (Detailed Description) The present disclosure relates generally to systems and methods for partitioning species. In some embodiments, such systems can be used to determine one or more types of cancer. For example, certain aspects are generally directed to aqueous multi-phase partitioning systems that can be used, for example, to distinguish between various types of cancer, to diagnose subjects with cancer, and the like. In some cases, such systems can be used to determine the presence or absence of a species by using solvent properties, for example, the difference in solvent dipolarity / polarizability (Δπ) between the two phases of the partitioning system. *), the difference in solvent hydrogen bond donor acidity (Δα), the difference in solvent hydrogen bond acceptor basicity (Δβ), and the difference in electrostatic properties (c). These may be within specific ranges according to various embodiments. Furthermore, these ranges may be precisely tuned by controlling the composition of the phases of the partitioning system, producing novel partitioning systems that are unexpectedly efficient in distinguishing even relatively minor structural changes in proteins or other species, and thus may be used to distinguish various types of cancers or for other applications.
[0018] One embodiment is generally directed to a single partitioning system that can be used to determine separate partition coefficients (K) of the same protein for samples corresponding to different cancers or other conditions. This is surprising in light of previous studies that showed that the same protein partitioned into all cancer samples would behave the same (i.e., with similar K values) for all cancers, indicating that the same protein will partition in the same manner despite originating from different cancers.
[0019] In general, changes to the structure of proteins resulting from cancer (or other conditions) revealed using partitioning systems such as those described herein would be expected to be similar between different cancers, given the similarity of the cancer biology (e.g., post-translational modifications, metabolic changes, etc.) that leads to such changes. Surprisingly, however, some types of partitioning systems (including those described herein) can produce distinct partitioning behaviors for the same protein arising from different types of cancer. Partitioning systems that exhibit such anomalous behavior are difficult to identify, and cannot be identified by simply inspecting the components that form the partitioning system, given the vast range of chemical space that forms such systems. Instead, such partitioning behaviors may be due to specific solvent properties, such as differences in the dipolarity / polarizability (Δπ) of the solvent. *), the difference in hydrogen bond donor acidity of the solvent (Δα), the difference in hydrogen bond acceptor basicity of the solvent (Δβ), and the difference in electrostatic properties (c). These can be controlled not only by the components that form the partitioning system, but also by the concentrations of those components. It is believed that compositions that exhibit solvent properties, such as those described herein, are important for identifying partitioning systems that exhibit suitable properties to allow proteins arising from various cancers to be partitioned in a separate manner, for example, in a manner that allows the cancer in which the protein occurs to be determined. Thus, various embodiments, such as those described herein, are generally directed to partitioning systems that exhibit a particular combination of solvent properties. These can be described, measured, and determined as discussed herein.
[0020] It should be noted that various partitioning systems with different chemical components or ingredients may still exhibit the same solvent properties. Without wishing to be bound by any theory, it is believed that the interaction of a protein (or other species) with two or more solvents with different intermolecular properties is governed by certain solvent properties, such as those described herein. Thus, as discussed herein, certain types of partitioning systems are described by their solvent properties. While the solvent properties described and utilized in certain embodiments may be convenient to use and / or may be experimentally available, other properties may also be used to describe the solvent structure of interest and / or to analyze the solvent:solute molecular interactions, including those that result in the differential partitioning observed in aqueous two-phase partitioning systems. Furthermore, the partitioning system may include two phases, or in some cases, more than two phases. Furthermore, in some embodiments, some or all of the phases in the partitioning system may be aqueous.
[0021] Cancer is generally caused by mutations that can cause changes to the coding, translation, and / or post-translational events during protein synthesis, including some well-known global intercellular environment modifications caused by metabolic changes.All of these can combine to cause various structural changes to proteins or other species, which can be correlated with cancer in proteins and their interactions.This characteristic can be used for diagnostic or treatment purposes, for example, as discussed herein.
[0022] It is important to note that certain modifications to the structure are consistently found among proteins produced in the altered metabolic environment of cancer cells (e.g., certain post-translational modifications such as glycosylation). Such structural changes may affect the entire repertoire of protein biomarkers of interest (e.g., glycoproteins) or other biomarkers (e.g., biomarkers described herein). Thus, although each protein may have distinct primary, secondary, and tertiary structures, the specific alterations to its higher-order structure in the presence of cancer metabolism are specific and may be determined using generalized means, such as those described herein, that may be able to resolve such differences.
[0023] In certain embodiments, when describing a particular composition of a partitioning system, the starting chemical composition or starting chemical components (e.g., amount and type of polymer, salt, etc.) can be used. However, this description does not fully describe the molecular properties of the solvent phase that result in the observed partitioning behavior of the solute (e.g., protein) due to the differential interaction with the solvent phase. In contrast, these solvent-solute molecular interactions are extremely complex. Although a thermodynamic phase diagram can be empirically created from the initial starting chemical components of the phases of the partitioning system, such a phase diagram is often insufficient to accurately describe the observed partitioning behavior of the solute in the partitioning system. Thus, reciting the initial chemical components of the partitioning system by the starting chemical components of the partitioning system does not fully predict the specific relationship between the partitioning system and the partitioning behavior of the solute. In fact, various partitioning systems with similar chemical compositions can show substantially different partitioning behavior for a certain solute, while conversely, substantially different starting chemical compositions can result in partitioning systems that show the same partitioning behavior for the same solute.
[0024] As discussed herein, improved methodologies for predicting the observed partition behavior of solutes in partitioning systems include the use of specific solvent properties, such as the difference in solvent dipolarity / polarizability (Δπ * ), the difference in hydrogen bond donor acidity of the solvent (Δα), the difference in hydrogen bond acceptor basicity of the solvent (Δβ), and the difference in electrostatic properties (c). These are discussed in more detail herein. Various specific combinations of these solvent properties result in novel formulations that are surprisingly effective in partitioning specific types of solutes (e.g., proteins). For example, the specific partitioning system described herein can be used to distinguish between different types of cancer. For example, the same protein arising from different subjects (e.g., different people with different cancers) may partition differently, depending on, for example, the type of cancer. This is surprising because, as mentioned above, previous studies have shown that the same protein partitioned into all cancer samples would have behaved the same way, even if it arose from different types of cancer, as expected.
[0025] In some embodiments, the partitioning system may generally be relatively sensitive to differences in the structure of a particular solute (e.g., protein or protein biomarker) corresponding to various cancers described with respect to a particular solvent property. In one embodiment, four solvent properties are used to define the solute-solvent interactions between various phases that form the basis of the novel partitioning system described herein. Such solvent properties may be achieved in certain embodiments by a particular combination of solvents, polymers, salts, etc., which combinations may be determined as described herein.
[0026] Thus, in some embodiments, the same protein (or other solute) produced in various cancers can be determined using the same partitioning system. The variability of the partitioning behavior of the protein can be consistent on average for each cancer, but can vary between cancers. Thus, a sample (e.g., blood or other clinically obtained sample) can be introduced into a single partitioning system, and then, after partitioning, the protein can be determined by measuring the concentration of the protein in the partitioning system phase, for example, with a suitable immunoassay (e.g., ELISA). In some cases, the same can be repeated for additional proteins (or other solutes) in the same sample partitioned using the corresponding immunoassay. Such partitioning behavior (e.g., as a single protein or as a signature composed of multiple proteins, etc.) can then be determined, for example, as a partition coefficient (K), or other suitable metric. In some embodiments, comparing the partition coefficient (or other metric) with a previously known value (e.g., corresponding to partition coefficients obtained for various cancers) can then be used to determine the type of cancer or otherwise determine the clinical phenotype of the sample. Non-limiting examples of cancer include pharyngeal cancer, stomach cancer, pancreatic cancer, brain cancer, lung cancer, cervical cancer, prostate cancer, breast cancer, testicular cancer, ovarian cancer, oral cancer, pharyngeal cancer, esophageal cancer, and intestinal and intestinal cancer. Other examples of cancer are discussed in more detail below.
[0027] In some cases, more than one solute or species (e.g., more than one protein) can be determined, for example, in the same partition system or separate partition systems, for example, using their corresponding immunoassays or other determination methods.For example, in some cases discussed herein, the same partition system can show different types of partition behavior for different cancer types for two or more of its solutes.Therefore, by determining multiple solvents, the clinical diagnostic method or performance can be improved in some embodiments, for example, in terms of sensitivity and / or specificity.
[0028] Without wishing to be bound by any theory, it is believed that the partitioning behavior of a solute (e.g., a protein) in a partitioning system formed by two nonionic polymers or by a single polymer and a salt is governed by various types of interactions between the solute in the two phases and the aqueous medium. These include: (1) dipole-dipole interactions and dipole-induced dipole interactions (as discussed herein, π * (2) hydrogen bonding interactions with water acting as a hydrogen bond donor (quantifiable as α, as discussed herein); (3) hydrogen bonding interactions with water acting as a hydrogen bond acceptor (quantifiable as β, as discussed herein); and (4) electrostatic ion-dipole and ion-ion interactions (quantifiable as c, as discussed herein). These solvent properties, once quantified, can describe solute partitioning behavior with a relatively high degree of accuracy. In one set of embodiments, they can be used to determine the solute partition coefficient in a partitioning system (e.g., an aqueous two-phase system). logK s =S s Δπ * +B s Δα+A s Δβ+C s c In this formula, K s is the solute distribution coefficient; Δπ *, Δα, Δβ, and c are the differences between the solvent properties of the upper phase (solvent dipolarity / polarizability, hydrogen bond donor acidity, hydrogen bond acceptor basicity, and electrostatic properties, respectively) and the solvent properties of the lower phase; S s , B s , A s , and C s is a constant (solute-specific coefficient) describing the complementary interaction of that solute with the solvent medium in the coexisting phase; the subscript "s" denotes the solute.
[0029] The solvent dipolarity / polarizability, solvent hydrogen bond donor acidity, and solvent hydrogen bond acceptor basicity of each phase of the partitioning system can in some embodiments be determined by the addition of a solvatochromic dye, e.g., 4-nitroanizole (solvent dipolarity / polarizability π * The hydrogen bond donor capacity of a solvent can be quantified using the following dyes: 4-nitrophenol (to estimate the hydrogen bond acceptor capacity of the solvent, β), and the water-soluble solvatochromic Reichardt carboxylated betaine dye, sodium {2,6-diphenyl-4-[4-(4-carboxylato-phenyl)-2,6-diphenylpyridinium-1-yl])phenolate} (to estimate the hydrogen bond donor capacity of the solvent, α). Exemplary protocols for measuring such solvent properties are described in Madeira et al., "Solvent Properties Governing Solute Partitioning in Polymer / Polymer Aqueous Two-Phase Systems: Nonionic Compounds," J. Phys. Chem. B., 114(1):457-462, 2010; and Madeira et al., "Solvent Properties Governing Protein Partitioning in Polymer / Polymer Aqueous Two-Phase Systems," J. Chromatogr. A, 1218(10):1379-1384, 2011, each of which is incorporated by reference in its entirety. The difference (i.e., Δ) between the solvent properties of the phases of a partitioning system is calculated as the difference between the phases of the partitioning system.
[0030] Solvent dipolarity / polarizability difference (Δπ * ) is the dipolarity / polarizability (π * ) can be determined as the difference between π * is generally a measure of the degree of stabilization of the solvent with respect to charges or dipoles, and can be altered in the partitioning system by using charged nucleic acids (e.g., arginine, lysine, etc.). * is the wave number (ν1) of the longest wavelength absorption band of 4-nitroanisole in each phase in cm -1 Measure in units of π in each phase * It can be determined separately in each phase by calculating v = 0.427 (34.12 - v).
[0031] The difference in hydrogen bond donor acidity (Δα) of a solvent can be determined as the difference between the hydrogen bond donor acidities (α) of the phases of the partitioning system. α is generally a measure of the tendency of a solvent molecule to donate a proton in a hydrogen bond with a solute molecule, and can be modified in the partitioning system by using osmolytes, such as trimethylamine N-oxide (TMAO), dimethylsulfoniopropionate, sarcosine, betaine, glycerophosphorylcholine, myo-inositol, taurine, glycine, and the like. α can be determined by measuring the maximum wavelength (λ) of the absorption band of carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932)[(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * The kinetics of the oxidative stress can be determined separately in each phase by calculating:
[0032] The difference in hydrogen bond acceptor basicity (Δβ) of a solvent can be determined as the difference between the hydrogen bond acceptor basicities (β) of the phases of the partitioning system. β is generally a measure of the ability of a solvent to accept a hydrogen bond in a solute-solvent hydrogen bonding interaction or to donate an electron pair in a solute-solvent coordinate bond. It can be modified in the partitioning system by adding sugars, such as glucose, trehalose, sucrose, galactose, fructose, etc. β is expressed as the wave number (ν2) of the longest wavelength absorption band of 4-nitrophenol in each phase in cm -1 The units are 0.346(35.045-ν2)-0.57π, and the β in each phase is 0.346(35.045-ν2)-0.57π. * The kinetics of the oxidative stress can be determined separately in each phase by calculating:
[0033] The difference (c) between the electrostatic properties of the phases can be determined by analysis of the partition coefficients of a series of homologous sodium salts of dinitrophenylated (DNP-) amino acids with aliphatic alkyl side chains (DNP-glycine, DNP-alanine, DNP-norvaline, DNP-norleucine, and DNP-α-amino-n-octanoic acid). These compounds are water-soluble and colored, which makes it convenient to assay their concentrations in the phases using direct absorbance measurements with a UV-VIS spectrophotometer at 360 nm. The logarithm of the partition coefficients of the DNP-amino acid Na salts corresponds to the number of methylene group equivalents (N c When the length of the side chain is plotted against the length of the side chain, expressed as log K i DNP-AA =c i +E i N c In this formula, K DNP-AA is the partition coefficient of DNP-amino acid Na salt; N c is the number of equivalents of CH groups in its side chain, and E and c are constants for a given ith ATPS that characterize the difference between the relative hydrophobicity and electrostatic properties of the phases.
[0034] Thus, in some embodiments, c can be calculated by separately distributing various dinitrophenylated amino acid sodium salts in a partitioning system, measuring the partition coefficient (K) of each sodium salt, and calculating K and the methylene equivalent (N) of each sodium salt. c ) to log 10 K=c+EN c to determine c and E. For example, the dinitrophenylated amino acid sodium salt can be dinitrophenylated alanine sodium salt (having an Nc of 1.31), dinitrophenylated norvaline sodium salt (having an Nc of 2.65), dinitrophenylated norleucine sodium salt (having an Nc of 3.75), and dinitrophenylated α-amino-n-octanoic acid sodium salt (having an Nc of 6.30).
[0035] In general, c is a measure of electrostatic effects that generally arise due to interactions of the solute's charges among themselves and with the solvent and ionic charges, and can be altered in a partitioning system by adding salts, such as NaCl, KCl, Cs2SO4, or other salts, including any of the salts described herein.
[0036] Non-limiting examples of partitioning systems having specific values for the above solvent properties not previously described are as follows: [Table 11]
[0037] Without wishing to be bound by any theory, it is believed that a partitioning system with these properties can be surprisingly effective in partitioning the same protein in a different manner depending on the cancer from which it originates. As discussed herein, in most partitioning systems, the same protein would be expected to partition in the same manner despite originating from different cancers. However, the particular partitioning system described herein has been found to be effective in partitioning the same protein in a different manner.
[0038] As noted above, in some embodiments, partitioning systems with identical or very close differences between the solvent properties of the phases can be produced using different polymer pairs, different molecular weights and / or concentrations of polymers, non-ionic additives, different types of buffers and other additives. As a non-limiting example, a partitioning system formed from 15.1 wt% Ficoll®-70 kDa, 7.9 wt% PEG-8 kDa, and 0.15 M NaCl in 0.01 M sodium phosphate buffer (pH 7.4) had a difference between the dipolarity / polarizability of the solvents of the coexisting phases (Δπ * ) -0.052, the difference between the hydrogen bond donor acidities of the solvents of the coexisting phases (Δα) value of 0.023, the difference between the hydrogen bond acceptor basicities of the solvents of the coexisting phases (Δβ) -0.022, and the difference between the electrostatic properties of the coexisting phases (c) -0.092. A partitioning system formed from 12.9 wt% Dextran-70 kDa, 17.5 wt%. Ficoll®-70 kDa, 0.10 M Cs2SO4 in 0.01 M sodium phosphate buffer (pH 7.4) has a difference between the dipolarity / polarizability of the solvents of the coexisting phases (Δπ * ) -0.056, the difference between the hydrogen bond donor acidities of the solvents of the coexisting phases (Δα) 0.020, the difference between the hydrogen bond acceptor basicities of the solvents of the coexisting phases (Δβ) -0.019, and the difference between the electrostatic properties of the coexisting phases (c) -0.093. Thus, even though these two exemplary partitioning systems are formed from separate salts, sugars, etc., they exhibit very similar partitioning behavior.
[0039] As discussed, the partitioning system may be an aqueous two-phase partitioning system in certain embodiments, or an aqueous multiphase partitioning system in certain embodiments. Aqueous two-phase systems may occur in aqueous mixtures of various water-soluble polymers, or in aqueous mixtures of a single polymer and a specific salt. When two specific polymers (e.g., dextran (Dex) and polyethylene glycol (PEG)), or a single specific polymer and a specific inorganic salt (e.g., polyvinylpyrrolidone (PVP) and sodium sulfate) are mixed in water above a certain concentration, the mixture separates into two immiscible aqueous phases. There is a discontinuous interface separating the two phases, one rich in one polymer and the other rich in the other polymer or inorganic salt. The aqueous solvent in both phases may provide a suitable medium for biological materials. Two-phase systems may be generalized to multiphase systems by using various chemical components, and aqueous systems with 12 or more phases have been described in the literature.
[0040] Aqueous two-phase systems occur in aqueous mixtures of various water-soluble polymers or in aqueous mixtures of a single polymer with a particular salt. For example, when dextran and polyethylene glycol ("PEG") are mixed in water above a certain concentration, the mixture separates into two immiscible aqueous phases separated by a distinct boundary surface. These two separate phases are said to be separated. In one phase, the solution is rich in one polymer, and on the other side of this boundary in the second phase, the solution is rich in the other polymer. Other examples of aqueous two-phase systems include PEG-Ucon (商標) (50-HB-5100, which is a copolymer of ethylene glycol and propylene glycol), Ucon (商標) - PVP, Ucon (商標)-PPG (polypropylene glycol), PEG-PAM (polyacrylamide), PAM-PVP, PAM-PPG (polypropylene glycol), PEG-Ficoll® (a neutral, hyperbranched, high molecular weight hydrophobic polymer prepared by copolymerization of sucrose with epichlorohydrin, available from GE Healthcare), PEG-PAM (polyacrylamide), PEG-PVP, PVP-PAM, and the like, but are not limited to these.
[0041] As used herein, "aqueous" refers to a characteristic property of a solvent / solute system in which the solvate has a predominantly hydrophilic character. Examples of aqueous solvent / solute systems include those in which water or a water-containing composition is the predominant solvent.
[0042] As used herein, "aqueous multi-phase system" refers to an aqueous system consisting of more than one aqueous phase in which an analyte species may exist, which may be used to characterize the structural state of the analyte species according to the methods described herein. For example, this includes aqueous systems that may separate into two, three, or more immiscible phases at equilibrium. Aqueous multi-phase systems are known in the art, and the phrase, as used herein, is not meant to be inconsistent with the art-accepted meaning.
[0043] Selection and modification of the type of polymers (e.g., as reflected in chemical nature, structure, and molecular weight) that form the phases, as well as the concentrations of the polymers, can be used to change the properties of the phases. Additionally, the composition of the phases can also be changed by the addition of inorganic salts and / or organic additives. Changes to the composition of the phases can change the properties of the phases. Examples of types of aqueous two-phase systems include, but are not limited to, dextran / PEG, dextran / polyvinylpyrrolidone, PEG / salt, and polyvinylpyrrolidone / salt.
[0044] In some embodiments, when a sample (e.g., of a biological fluid) (e.g., serum or plasma) is added to a partitioning system, a species present in the sample may partition independently between the phases, e.g., if the species does not interact with other species or other partners that may also be present. If such an interaction occurs, the species-partner complex itself may partition between the phases. The partitioning of a species (or a complex containing the species) may depend on various factors, e.g., the nature and three-dimensional arrangement of the solvent-exposed groups and the properties of the coexisting phases. The three-dimensional medium of the solvent-exposed groups may depend on various factors, e.g., the presence of salt additives, pH, etc. However, it should be emphasized that the exact nature of these interactions may not be known with certainty. As mentioned above, such partitioning systems may be based on the solvent properties, e.g., the difference in the dipolarity / polarizability of the solvent between the two phases of the partitioning system (Δπ * ), the difference in the hydrogen bond donor acidity of the solvent (Δα), the difference in the hydrogen bond acceptor basicity of the solvent (Δβ), and the difference in electrostatic properties (c) can be readily identified and / or distinguished from one another without necessarily having to identify each factor that may contribute to the interaction between a species and a phase of a partitioning system.
[0045] When a solute or other species is introduced into such a two-phase system, it distributes between the two phases. The partitioning of a solute can be quantified by the partition coefficient K, defined as the ratio between the concentrations of the solute in the two immiscible phases at equilibrium. Phase separation in aqueous polymer systems can result from the different effects of the two polymers (or a single polymer and a salt) on the water structure. As a result of their different effects on the water structure, the solvent characteristics of the aqueous media in the coexisting phases differ from each other. The differences between the phases can be demonstrated, for example, by dielectric, solvatochromic, potentiometric, and partitioning measurements.
[0046] Without wishing to be bound by any theory, it is believed that the partitioning of a species in an aqueous two-phase system depends on its three-dimensional structure and the type and topography of its solvent-exposed chemical groups. Changes in the receptor's three-dimensional structure induced by some action (e.g., by ligand binding or by structural degradation) also change the topography of the solvent-accessible chemical groups in the species, or both the topography and type of the solvent-accessible groups. One of the consequences of these changes is an alteration in the partitioning behavior of the species. As a result, by monitoring the partition coefficient of a species, it is possible to detect changes in the state of the structure for which the partition coefficient is known.
[0047] Similarly, such changes can be detected using other methods that have a fundamental dependence on the topography and / or type of solvent-accessible groups, including, but not limited to, column liquid-liquid partition chromatography (LLCP), heterogeneous biphasic or heterogeneous multiphasic systems.
[0048] In the case of such methods in determining coefficients reflecting relative partition (e.g., as partition coefficients), a single descriptor is obtained. Although many different aqueous two-phase systems all differ in their sensitivity to various chemical groups (e.g., charged and non-polar groups), the presence of detectable differences between two conformational states, in the form of changes in partition coefficients, can result from a large number of separate mechanisms. Thus, similar changes in a single partition coefficient can reflect very dissimilar conformational changes. Furthermore, in some cases, more than one partition coefficient is obtained, for example, as a signature. See, for example, U.S. Patent No. 7,968,350 (incorporated by reference in its entirety).
[0049] As used herein, "partition coefficient" refers to a coefficient defined by the ratio between the concentrations of a solute in two immiscible phases at equilibrium. For example, the partition coefficient (K) of an analyte in a two-phase system is defined as the ratio of the concentration of the analyte in a first phase to the concentration of that analyte in a second phase. For a multiphase system, there are multiple partition coefficients, each defining the ratio of the analyte in a selected first phase to the analyte in a selected second phase. It is recognized that the total number of partition coefficients in any multiphase system is equal to the total number of phases minus one.
[0050] Evaluation of data derived from species partitioning may include the use of partition coefficients ("K"), which are defined as the ratio between the concentrations of a certain species in two immiscible phases at equilibrium. For example, the partition coefficient K of a protein is defined as the ratio of that protein in the first phase to that protein in the second phase in a two-phase system. When a multiphase system is formed, there may be multiple independent partition coefficients that can be defined between any two phases. When considering mass balance, the number of independent partition coefficients is one less than the number of phases in the system.
[0051] It is recognized that the partition coefficient K for a given species of a given conformation is constant when the conditions and composition of the thermodynamic equilibrium two-phase system to which the species is subjected remain constant. Thus, if there are changes in the partition coefficient K observed for a protein upon addition of a potential binding partner, these changes can be presumed to result from changes in the protein structure caused by the formation of a protein-binding partner complex. As used herein, "K" is used as specifically defined mathematically herein, and in all cases, this "K" also includes, by definition, any coefficient that represents a relative measure of the interaction between a species and at least two interacting components.
[0052] The concentrations of species in each phase can be used to determine the partition coefficient, K, of a sample under particular system conditions. Since K reflects only the ratio of the two concentrations, its absolute value is typically not required. It will be appreciated that this may allow certain analytical procedures to be simplified, for example, calibration may be eliminated in some cases.
[0053] The partition coefficient, in some embodiments, may be compared to other K values. For example, the K value for a species may be compared to the K values for that species under various conditions, the K value for a species may be compared to the K values for that species in combination with other species, or one set of K values for a species may be compared to another set of K values.
[0054] In some cases, multiple partition coefficients (e.g., for various solutes) or other metrics can be assembled into a mathematical construct (e.g., a vector, signature, profile, pattern, etc.) of values that can be compared, for example, mathematically or statistically, against other standards (e.g., against a no comparative construct for a known type of cancer). The mathematical construct can include numbers, mathematical expressions, visual displays, or other techniques. In some embodiments, samples can also be partitioned using two or more different partitioning systems, and the partitioning behavior within the partitioning systems used to form the mathematical construct.
[0055] Thus, in certain embodiments, a pattern comprising partition coefficients corresponding to different protein biomarkers obtained from the same or different partition systems can be constructed so that it can provide specificity for cancer types. For example, vectors of partition coefficients for different proteins (or other species) and / or different partition systems can be used to determine or identify specific types of cancer. Such patterns can be determined, for example, using mathematical or statistical approaches, including machine learning, deep learning, multiple logistic regression, etc. Such patterns can be constructed in some cases using additional parameters, including clinically relevant parameters (such as age, race, other diagnostic information, etc.), or other species (such as biomarkers (such as DNA, RNA, etc.)).
[0056] As used herein, "signature" refers to a particular display of desired information, which can be defined as a set of relative measures of the above interactions obtained from experiments with various interacting components.Typically, signatures are used in place of more detailed information when such information is difficult to obtain or when such information is not necessary to fully describe in order to be utilized.For example, fingerprinting of individual people is a well-recognized technique for uniquely identifying an individual (with a reasonable degree of certainty), and provides a conveniently obtained and conveniently dense set of information instead of using other displays (e.g., genetic structure) or describing the individual by exhaustively using physical description and other information.
[0057] A variety of assay methods can be used, for example, to determine species (e.g., proteins) in one or more phases of a partitioning system. The assays often depend on the identity and type of species present. Examples of suitable assay techniques include, but are not limited to, spectroscopic, immunochemical, chemical, fluorescent, radioactive, and enzymatic assays. If the species is a peptide or protein, common peptide or protein detection techniques can be used. These include, but are not limited to, direct spectrophotometry (e.g., monitoring absorbance at 280 nanometers) and dye-binding reactions with Coomassie Blue G-250 or fluorescamine, o-phthaldialdehyde, or other dyes and / or reagents. In other embodiments, certain immunochemical assays (e.g., enzyme-linked immunosorbent assays (ELISAs)) can be used to determine species in some cases.
[0058] A sample of biological fluid may be collected from a subject, which may include fluids such as whole blood, serum, plasma, saliva, nasal fluid, sputum, urine, CNS fluid, nipple aspirate, cerebrospinal fluid, semen, etc. The subject from which the biological fluid is collected may be human or non-human, such as a non-human animal, including, but not limited to, dogs, cats, horses, cows, pigs, sheep, goats, chickens, primates, rats, and mice.
[0059] As mentioned above, various cancers can be determined in blood samples (or other suitable fluid samples). Examples of cancers include, but are not limited to, breast cancer, prostate cancer, lung cancer, ovarian cancer, colorectal cancer, and brain cancer. Other non-limiting examples of cancers include biliary tract cancer; bladder cancer; brain cancer (including glioblastoma and medulloblastoma); breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms (including acute lymphocytic leukemia and acute myeloid leukemia); multiple myeloma; AIDS-related leukemia and adult T-cell leukemia-lymphoma; intraepithelial neoplasms (including Bowen's disease and Paget's disease); liver cancer; lung cancer; lymphomas (including Hodgkin's disease and lymphocytic lymphoma). neuroblastoma; oral cancer (including squamous cell carcinoma); ovarian cancer (including ovarian cancer arising from epithelial cells, stromal cells, germ cells, and mesenchymal cells); pancreatic cancer; prostate cancer; rectal cancer; sarcomas (including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma); skin cancer (including melanoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell carcinoma); testicular cancer (including germinal tumors, e.g., seminoma, nonseminoma, teratoma, choriocarcinoma); stromal and germ cell tumors; thyroid cancer (including thyroid adenocarcinoma and medullar carcinoma); and renal cancer (including adenocarcinoma and Wilms' tumor).Still other examples of cancer include lymphomas, sarcomas, and carcinomas, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, synovium, mesothelioma, lymphangioendotheliosarcoma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, and the like. carcinoma), bronchogenic carcinoma, renal cell carcinoma, hepatoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung cancer, non-small cell lung cancer, small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma; leukemia, e.g., acute These include acute lymphocytic and acute myeloid leukemia (myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, and erythroleukemia); chronic leukemia (chronic myeloid (granulocytic) leukemia and chronic lymphocytic leukemia); and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, and heavy chain disease.
[0060] The following documents are incorporated by reference in their entirety: U.S. Patent Nos. 7,968,350; 8,041,513; 8,099,242; 8,211,714; 8,437,964; 9,354,229; and 9,678,076. Additionally, U.S. Provisional Patent Application No. 63 / 272,759, entitled "Partitioning Systems and Methods for Determining Multiple Types of Cancers," filed October 28, 2021, is incorporated by reference in its entirety.
[0061] The following examples are intended to illustrate certain embodiments of the present disclosure, but do not exemplify the full scope of the disclosure.
[0062] Example 1 In this example, we demonstrated that the partition coefficients of proteins in human serum from patients with various cancers differ significantly from the partition coefficients of the same proteins in serum from healthy donors, and that such differences depend on the type of cancer.
[0063] Pooled serum samples from healthy subjects (sample identifier 0651) and from patients with stage I ovarian cancer (sample identifier 4850) were obtained from Clinical Proteomics Reference Laboratory (Gaithersburg, MD). Pooled serum samples from patients with stage 1 breast cancer, stage 1 pancreatic cancer, and stage 1 prostate cancer were formed from individual samples obtained from SeraCare Life Sciences and PromedDx, Inc. Samples were obtained, frozen, and stored at -80°C. Patient diagnostic status was provided by their supplier.
[0064] Several aqueous two-phase partitioning systems (e.g., the following pairs) were prepared and used according to the protocol to estimate the appropriate coarse space: 6.1 wt% PEG-8000 / 12.4 wt% dextran-70K; 16 wt% PVP-40K / 15 wt% PEG-8000; 16 wt% polyacrylamide (PAM-10,000) / 8 wt% PEG-8000; 15.0 wt% PVP-40K / 19.0 wt% PAM-10000; and 7.9 wt% PEG-8000 / 15.1 wt% Ficoll®, all prepared with 0.01 M sodium / potassium phosphate buffer at pH 7.4.
[0065] The aqueous two-phase system ("ATPS") consisted of two non-ionic polymers, phosphate buffer (pH 7.4), and NaCl (ATPS#1). Breast, prostate, pancreatic, and ovarian cancer plasma pools, as well as a control (normal plasma), were prepared from approximately 10 individual samples each. Immunoassays for the protein biomarkers in Table 2 were used as follows. A complex sparse DOE-RSD analysis was performed according to the protocol to achieve the desired solvent parameters shown in Table 1. The specific partition coefficients of the various protein biomarker candidates for the various cancer and control samples are shown in Table 2. The details of the experimental protocol are described below. The composition corresponding to the solvent parameters in Table 2 included 7.9 wt% PEG-8000, 15.1 wt% Ficoll®, 0.25 M NaCl, 0.5 M Arginine HCl, and 0.11 M phosphate buffer (pH 7.4). The difference between the solvent characteristics of the two coexisting phases was characterized. The differences are presented below in Table 1. They were measured as described in Example 6.
[0066] The aqueous two-phase systems were prepared by mixing appropriate amounts of stock polymer, salt and buffer solutions and dispensed by a liquid handling workstation Hamilton ML-4000 into microtubes with a total volume of 1.2 mL to a total volume of 440 microliters of the mixture. 40 microliters of each serum sample was added to the system. The ratio between the volumes of the two phases of each system with a final volume of 480 microliters was approximately 1:1. The systems were vigorously shaken and centrifuged at 3500 g for 45 minutes in a refrigerated centrifuge equipped with a microplate rotor, the temperature of which was maintained at 23° C. to accelerate the phase sedimentation. The microtubes were removed from the centrifuge and 40 microliter aliquots from the upper phase and 40 microliter aliquots from the lower phase were removed in duplicate, each diluted 5-fold, mixed with the appropriate reagents as indicated below, and used for further analysis performed as described below.
[0067] LabMAP technology (Luminex) combines the principles of sandwich immunoassays with fluorescent bead-based technology to allow multiplex analysis of up to 100 separate analytes in a single microtiter well. LabMAP assays were performed in a 96-well microplate format following the protocol from Biosource International (Camarillo, CA). Filter-bottom 96-well microplates (Millipore, Billerica, MA) were blocked with phosphate-buffered saline / bovine serum albumin solution for 10 minutes. Five-fold dilutions of appropriate standards were prepared in serum diluent to generate standard curves. Standards and patient sera were pipetted in duplicate at 50 microliters per well and mixed with 50 microliters of bead mixture. The microplate was incubated for 1 hour at room temperature on a microplate shaker. The wells were then washed three times with wash buffer using a vacuum manifold. Phycoerythrin (PE-) conjugated secondary antibodies were added to the appropriate wells and the wells were incubated in the dark for 45 minutes with constant shaking. The wells were washed twice, assay buffer was added to each well, and the samples were assayed using a Bio-Plex Suspension Array System (Bio-Rad Laboratories, Hercules, CA). The molecular characteristics of ATPS#1 are shown in Table 1, and analysis of the experimental data was performed using a five-parameter curve fitting. The results, expressed as the ratio of the concentration of a given antigen in the top phase to the concentration of a given antigen in the bottom phase (i.e., the partition coefficient), are presented in Table 2, which shows the difference between the solvent characteristics of the top phase and the bottom phase for ATPS#1, and the partition coefficients for various antigens in serum. [Table 1] [Table 2]
[0068] IGFBP-1: insulin-like growth factor binding protein 1; ErbB2 or Her2, a protein member of a family of receptor tyrosine kinases structurally related to the epidermal growth factor receptor (EGFR); MMP2: matrix metallopeptidase 2; MMP9: matrix metallopeptidase 9; MPO: myeloperoxidase; RANTES: chemokine; sIL-6R: soluble IL-6 receptor; TSP: thrombospondin.
[0069] The data presented in Table 1 show that the patterns of partition coefficients for the set of antigens listed differ between healthy controls and sera from patients with the various cancers tested (breast, ovarian, pancreatic, and prostate). Individual biomarker patterns can be used to confer cancer specificity, or a set of biomarkers can be combined to derive higher dimensional patterns with even greater specificity.
[0070] Example 2 In this example, using a different ATPS than in Example 1, we demonstrated that the partition coefficients of proteins in human serum from patients with various cancers are significantly different from the partition coefficients of the same proteins in serum from healthy donors, and that such differences depend on the type of cancer.
[0071] Pooled serum samples from healthy subjects (sample identifier 0651) and from patients with stage I ovarian cancer (sample identifier 4850) were obtained from Clinical Proteomics Reference Laboratory (Gaithersburg, MD). Pooled serum samples from patients with stage 1 breast cancer, stage 1 pancreatic cancer, and stage 1 prostate cancer were formed from individual samples obtained from SeraCare Life Sciences and PromedDx, Inc. Samples were obtained, frozen, and stored at -80°C. Patient diagnostic status was provided by their supplier.
[0072] Several aqueous two-phase partitioning systems (e.g., the following pairs) were prepared and used according to the protocol to estimate the appropriate coarse space: 6.1 wt% PEG-8000 / 12.4 wt% dextran-70K; 12 wt% PVP-40K / 17 wt% PEG-8000; 18 wt% polyacrylamide (PAM-10,000) / 6 wt% PEG-8000; 15.0 wt% PVP-40K / 19.0 wt% PAM-10000; and 9 wt% PEG-8000 / 15 wt% Ficoll®, all prepared with 0.01 M sodium / potassium phosphate buffer at pH 7.4.
[0073] The aqueous two-phase system consisted of two non-ionic polymers, phosphate buffer (pH 7.4), and NaCl (ATPS#2). Breast, prostate, pancreatic, and ovarian cancer plasma pools, as well as a control (normal plasma), were prepared from approximately 10 individual samples each. Immunoassays for protein biomarkers in Table 4 were used as follows. A complex sparse DOE-RSD analysis was performed according to the protocol to achieve the desired solvent parameters shown in Table 3. The specific partition coefficients of various protein biomarker candidates for various cancer and control samples are shown in Table 4. The details of the experimental protocol are described below. The composition corresponding to the solvent parameters in Table 4 included 18.2 wt% PVP-40K, 16.5 wt% PEG-8000, 1.5 M NaCl, 1.0 M TMAO, and 0.001 M phosphate buffer (pH 7.4). The difference between the solvent characteristics of the two coexisting phases was characterized. The differences are presented below in Table 3. They were measured as described in Example 6.
[0074] The aqueous two-phase systems were prepared by mixing appropriate amounts of stock polymer, salt and buffer solutions and dispensed by a liquid handling workstation Hamilton ML-4000 into microtubes with a total volume of 1.2 mL to a total volume of 440 microliters of the mixture. 40 microliters of each serum sample was added to the system. The ratio between the volumes of the two phases of each system with a final volume of 480 microliters was approximately 1:1. The systems were vigorously shaken and centrifuged at 3500 g for 45 minutes in a refrigerated centrifuge equipped with a microplate rotor, the temperature of which was maintained at 23° C. to accelerate the phase sedimentation. The microtubes were removed from the centrifuge and 40 microliter aliquots from the upper phase and 40 microliter aliquots from the lower phase were removed in duplicate, each diluted 5-fold, mixed with the appropriate reagents as indicated below, and used for further analysis performed as described below.
[0075] LabMAP technology (Luminex) combines the principles of sandwich immunoassays with fluorescent bead-based technology to allow multiplex analysis of up to 100 separate analytes in a single microtiter well. LabMAP assays were performed in a 96-well microplate format following the protocol from Biosource International (Camarillo, CA). Filter-bottom 96-well microplates (Millipore, Billerica, MA) were blocked with phosphate-buffered saline / bovine serum albumin solution for 10 minutes. Five-fold dilutions of appropriate standards were prepared in serum diluent to generate standard curves. Standards and patient sera were pipetted in duplicate at 50 microliters per well and mixed with 50 microliters of bead mixture. The microplate was incubated for 1 hour at room temperature on a microplate shaker. The wells were then washed three times with wash buffer using a vacuum manifold. Phycoerythrin (PE-) conjugated secondary antibodies were added to the appropriate wells and the wells were incubated in the dark for 45 minutes with constant shaking. Wells were washed twice, assay buffer was added to each well, and samples were assayed using a Bio-Plex Suspension Array System (Bio-Rad Laboratories, Hercules, CA). Analysis of the experimental data was performed using a 5-parameter curve fitting. The results, expressed as the ratio of the concentration of a given antigen in the top phase to the concentration of a given antigen in the bottom phase (i.e., the partition coefficient), are presented in Table 4, which shows the difference between the solvent characteristics of the top and bottom phases for ATPS#2, and the partition coefficients for various antigens in serum. Table 3 describes the molecular properties of ATPS#2. [Table 3] [Table 4]
[0076] EGFR: epidermal growth factor receptor; sICAM-1: soluble intercellular adhesion molecule 1; sVCAM-1: circulating vascular cell adhesion molecule 1; other abbreviations are as provided in Table 1.
[0077] The data presented in Table 4 show that the patterns of partition coefficients for the set of listed antigens are different between healthy controls and sera from patients with various cancers tested (breast, ovarian, pancreatic, and prostate cancer). These data are also different from the data presented in Table 2 for ATPS#1. Individual biomarker patterns can be used to provide cancer specificity, or a set of biomarkers can be combined to derive higher dimensional patterns with further enhanced specificity. Furthermore, combining partition information from at least two separate ATPSs and distinct molecular features for the same or separate biomarkers into one pattern can further enhance overall specificity.
[0078] Example 3 In this example, using yet another ATPS, we demonstrated that the partition coefficients of proteins in human serum from patients with various cancers differ significantly from the partition coefficients of the same proteins in serum from healthy donors, and that such differences depend on the type of cancer.
[0079] Pooled serum samples from healthy subjects (sample identifier 0651) and from patients with stage I ovarian cancer (sample identifier 4850) were obtained from Clinical Proteomics Reference Laboratory (Gaithersburg, MD). Pooled serum samples from patients with stage 1 breast cancer, stage 1 pancreatic cancer, and stage 1 prostate cancer were formed from individual samples obtained from SeraCare Life Sciences and PromedDx, Inc. Samples were obtained, frozen, and stored at -80°C. Patient diagnostic status was provided by their supplier.
[0080] Several aqueous two-phase partitioning systems (e.g., the following pairs) were prepared and used according to the protocol to estimate the appropriate coarse space: 14 wt% PVP-40K / 16 wt% PEG-8000; 16 wt% polyacrylamide (PAM-10,000) / 8 wt% PEG-8000; 14.0 wt% PVP-40K / 20.0 wt% PAM-10000; and 7.9 wt% PEG-8000 / 15.1 wt% Ficoll®, all prepared with 0.01 M sodium / potassium phosphate buffer at pH 7.4.
[0081] The aqueous two-phase system consisted of two non-ionic polymers, phosphate buffer (pH 7.4), and NaSCN additive (ATPS#3). Breast, prostate, pancreatic, and ovarian cancer plasma pools, as well as control (normal plasma), were prepared from approximately 10 individual samples each. Immunoassays for protein biomarkers in Table 6 were used as follows. Composite sparse DOE-RSD analysis was performed according to the protocol to achieve the desired solvent parameters shown in Table 5. The specific partition coefficients of various protein biomarker candidates for various cancer and control samples are shown in Table 6. The details of the experimental protocol are described below. The compositions corresponding to the solvent parameters in Table 6 included 8.7 wt% PEG-8000, 16.3 wt% Ficoll®-70, 0.75 M NaSCN, 0.5 M trehalose, and 0.11 M phosphate buffer (pH 7.4). The differences between the solvent profiles of the two coexisting phases were characterized and are presented below in Table 5. These were measured as described in Example 6.
[0082] The aqueous two-phase systems were prepared by mixing appropriate amounts of stock polymer, salt and buffer solutions and dispensed by a liquid handling workstation Hamilton ML-4000 into microtubes with a total volume of 1.2 mL to a total volume of 440 microliters of the mixture. 40 microliters of each serum sample was added to the system. The ratio between the volumes of the two phases of each system with a final volume of 480 microliters was approximately 1:1. The systems were vigorously shaken and centrifuged at 3500 g for 45 minutes in a refrigerated centrifuge equipped with a microplate rotor, the temperature of which was maintained at 23° C. to accelerate the phase sedimentation. The microtubes were removed from the centrifuge and 40 microliter aliquots from the upper phase and 40 microliter aliquots from the lower phase were removed in duplicate, each diluted 5-fold, mixed with the appropriate reagents as indicated below, and used for further analysis performed as described below.
[0083] LabMAP technology (Luminex) combines the principles of sandwich immunoassays with fluorescent bead-based technology to allow multiplex analysis of up to 100 separate analytes in a single microtiter well. LabMAP assays were performed in a 96-well microplate format following the protocol from Biosource International (Camarillo, CA). Filter-bottom 96-well microplates (Millipore, Billerica, MA) were blocked with phosphate-buffered saline / bovine serum albumin solution for 10 minutes. Five-fold dilutions of appropriate standards were prepared in serum diluent to generate standard curves. Standards and patient sera were pipetted in duplicate at 50 microliters per well and mixed with 50 microliters of bead mixture. The microplate was incubated for 1 hour at room temperature on a microplate shaker. The wells were then washed three times with wash buffer using a vacuum manifold. Phycoerythrin (PE-) conjugated secondary antibodies were added to the appropriate wells and the wells were incubated in the dark for 45 minutes with constant shaking. The wells were washed twice, assay buffer was added to each well, and the samples were assayed using a Bio-Plex Suspension Array System (Bio-Rad Laboratories, Hercules, CA). Analysis of the experimental data was performed using a 5-parameter curve fitting. The results, expressed as the ratio of the concentration of a given antigen in the upper phase to the concentration of a given antigen in the lower phase (i.e., the partition coefficient), are presented in Table 6, which shows the difference between the solvent characteristics of the upper phase and the lower phase, and the partition coefficients for various antigens in serum. Table 5 gives the molecular characteristics of ATPS#3. [Table 5] [Table 6]
[0084] EGFBP: insulin-like growth factor binding protein; other abbreviations are given above.
[0085] The data presented in Table 6 show that the patterns of partition coefficients for the set of listed antigens are different between healthy controls and sera from patients with various cancers (breast, ovarian, pancreatic, and prostate) tested. These data are also different from the data presented in Tables 2 and 4 for ATPS#1 and ATPS#2, respectively. The patterns of individual biomarkers can be used to provide cancer specificity, or a set of biomarkers can be combined to derive a higher dimensional pattern with further enhanced specificity. Furthermore, combining partition information from at least two separate ATPSs and distinct molecular features for the same or separate biomarkers into one pattern can further enhance overall specificity.
[0086] Example 4 In this example, we demonstrated that the partition coefficients of proteins in human serum from patients with various cancers in yet another ATPS differ significantly from the partition coefficients of the same proteins in serum from healthy donors, and that such differences depend on the type of cancer.
[0087] Pooled serum samples from healthy subjects (sample identifier 0651) and from patients with stage I ovarian cancer (sample identifier 4850) were obtained from Clinical Proteomics Reference Laboratory (Gaithersburg, MD). Pooled serum samples from patients with stage 1 breast cancer, stage 1 pancreatic cancer, and stage 1 prostate cancer were formed from individual samples obtained from SeraCare Life Sciences and PromedDx, Inc. Samples were obtained, frozen, and stored at -80°C. Patient diagnostic status was provided by their supplier.
[0088] A number of aqueous two-phase partitioning systems (e.g., the following pairs) were prepared and used according to the protocol as in Example 1 to estimate the appropriate coarse space: 6.1 wt% PEG-8000 / 12.4 wt% Dextran-70K; 16 wt% PVP-40K / 15 wt% PEG-8000; 16 wt% polyacrylamide (PAM-10,000) / 8 wt% PEG-8000; 15.0 wt% PVP-40K / 19.0 wt% PAM-10000; and 7.9 wt% PEG-8000 / 15.1 wt% Ficoll®. All were prepared using 0.01 M sodium / potassium phosphate buffer at pH 7.4.
[0089] The aqueous two-phase system consisted of two non-ionic polymers, phosphate buffer (pH 7.4), and NaCl (ATPS#4). Breast, prostate, pancreatic, and ovarian cancer plasma pools, as well as a control (normal plasma), were prepared from approximately 10 individual samples each. Immunoassays for protein biomarkers in Table 8 were used as described below. A complex sparse DOE-RSD analysis was performed according to the protocol to achieve the desired solvent parameters shown in Table 7. The specific partition coefficients of various protein biomarker candidates for various cancer and control samples are shown in Table 8. The details of the experimental protocol are described below. The compositions corresponding to the solvent parameters in Table 8 included 17.0 wt% PVP-40K, 20.5 wt% PAM-10K, 0.25 M Na2SO4, 1.5 M TMAO, and 0.01 M phosphate buffer (pH 7.4). The differences between the solvent characteristics of the two coexisting phases were characterized. The differences are presented below in Table 7. They were measured as described in Example 6.
[0090] The aqueous two-phase systems were prepared by mixing appropriate amounts of stock polymer, salt and buffer solutions and dispensed by a liquid handling workstation Hamilton ML-4000 into microtubes with a total volume of 1.2 mL to a total volume of 440 microliters of the mixture. 40 microliters of each serum sample was added to the system. The ratio between the volumes of the two phases of each system with a final volume of 480 microliters was approximately 1:1. The systems were vigorously shaken and centrifuged at 3500 g for 45 minutes in a refrigerated centrifuge equipped with a microplate rotor, the temperature of which was maintained at 23° C. to accelerate the phase sedimentation. The microtubes were removed from the centrifuge and 40 microliter aliquots from the upper phase and 40 microliter aliquots from the lower phase were removed in duplicate, each diluted 5-fold, mixed with the appropriate reagents as indicated below, and used for further analysis performed as described below.
[0091] LabMAP technology (Luminex) combines the principles of sandwich immunoassays with fluorescent bead-based technology to allow multiplex analysis of up to 100 separate analytes in a single microtiter well. LabMAP assays were performed in a 96-well microplate format following the protocol from Biosource International (Camarillo, CA). Filter-bottom 96-well microplates (Millipore, Billerica, MA) were blocked with phosphate-buffered saline / bovine serum albumin solution for 10 minutes. Five-fold dilutions of appropriate standards were prepared in serum diluent to generate standard curves. Standards and patient sera were pipetted in duplicate at 50 microliters per well and mixed with 50 microliters of bead mixture. The microplate was incubated for 1 hour at room temperature on a microplate shaker. The wells were then washed three times with wash buffer using a vacuum manifold. Phycoerythrin (PE-) conjugated secondary antibodies were added to the appropriate wells and the wells were incubated in the dark for 45 minutes with constant shaking. Wells were washed twice, assay buffer was added to each well, and samples were assayed using a Bio-Plex Suspension Array System (Bio-Rad Laboratories, Hercules, CA). Analysis of the experimental data was performed using a 5-parameter curve fitting. The results, expressed as the ratio of the concentration of a given antigen in the top phase to the concentration of a given antigen in the bottom phase (i.e., the partition coefficient), are presented in Table 8, which shows the difference between the solvent characteristics of the top phase and the bottom phase, and the partition coefficients for various antigens in serum. Table 7 shows the molecular properties of ATPS#4. [Table 7] [Table 8]
[0092] All abbreviations are given in the table above.
[0093] The data presented in Table 8 show that the patterns of partition coefficients for the set of listed antigens are different between healthy controls and sera from patients with various cancers (breast, ovarian, pancreatic, and prostate) tested. These data are also different from the data presented in Tables 2, 4, and 6 for ATPS#1, ATPS#2, and ATPS#3, respectively. The patterns of individual biomarkers can be used to provide cancer specificity, or a set of biomarkers can be combined to derive a higher dimensional pattern with further enhanced specificity. Furthermore, combining partition information from at least two separate ATPSs and distinct molecular features for the same or separate biomarkers into one pattern can further enhance overall specificity.
[0094] Example 5 In this example, we demonstrated that the partition coefficients of proteins in human serum from patients with different cancers in yet another ATPS differ significantly from the partition coefficients of the same proteins in serum from healthy donors, and that such differences depend on the type of cancer.
[0095] Pooled serum samples from healthy subjects (sample identifier 0651) and from patients with stage I ovarian cancer (sample identifier 4850) were obtained from Clinical Proteomics Reference Laboratory (Gaithersburg, MD). Pooled serum samples from patients with stage 1 breast cancer, stage 1 pancreatic cancer, and stage 1 prostate cancer were formed from individual samples obtained from SeraCare Life Sciences and PromedDx, Inc. Samples were obtained, frozen, and stored at -80°C. Patient diagnostic status was provided by their supplier.
[0096] Several aqueous two-phase partitioning systems (e.g., the following pairs) were prepared and used according to the protocol as in Example 3 to estimate the appropriate coarse space: 14 wt% PVP-40K / 16 wt% PEG-8000; 16 wt% polyacrylamide (PAM-10,000) / 8 wt% PEG-8000; 14.0 wt% PVP-40K / 20.0 wt% PAM-10000; and 7.9 wt% PEG-8000 / 15.1 wt% Ficoll®, all prepared with 0.01 M sodium / potassium phosphate buffer at pH 7.4.
[0097] The aqueous two-phase system consisted of two non-ionic polymers, phosphate buffer (pH 7.4) (ATPS#5). Breast, prostate, pancreatic and ovarian cancer plasma pools, and control (normal plasma) were prepared from approximately 10 individual samples each. Immunoassays for protein biomarkers in Table 10 were used as follows. Complex sparse DOE-RSD analysis was performed according to the protocol to achieve the desired solvent parameters shown in Table 9. The specific partition coefficients of various protein biomarker candidates for various cancer and control samples are shown in Table 10. The details of the experimental protocol are described below. The composition corresponding to the solvent parameters in Table 10 included 8.0 wt% PEG-8000, 15.5 wt% Ficoll®-70, and 18.0 wt% phosphate buffer (pH 7.4). The differences between the solvent characteristics of the two coexisting phases were characterized. These differences are presented in Table 9 below. These were measured as described in Example 6.
[0098] The aqueous two-phase systems were prepared by mixing appropriate amounts of stock polymer, salt and buffer solutions and dispensed by a liquid handling workstation Hamilton ML-4000 into microtubes with a total volume of 1.2 mL to a total volume of 440 microliters of the mixture. 40 microliters of each serum sample was added to the system. The ratio between the volumes of the two phases of each system with a final volume of 480 microliters was approximately 1:1. The systems were vigorously shaken and centrifuged at 3500 g for 45 minutes in a refrigerated centrifuge equipped with a microplate rotor, the temperature of which was maintained at 23° C. to accelerate the phase sedimentation. The microtubes were removed from the centrifuge and 40 microliter aliquots from the upper phase and 40 microliter aliquots from the lower phase were removed in duplicate, each diluted 5-fold, mixed with the appropriate reagents as indicated below, and used for further analysis performed as described below.
[0099] LabMAP technology (Luminex) combines the principles of sandwich immunoassays with fluorescent bead-based technology to allow multiplex analysis of up to 100 separate analytes in a single microtiter well. LabMAP assays were performed in a 96-well microplate format following the protocol from Biosource International (Camarillo, CA). Filter-bottom 96-well microplates (Millipore, Billerica, MA) were blocked with phosphate-buffered saline / bovine serum albumin solution for 10 minutes. Five-fold dilutions of appropriate standards were prepared in serum diluent to generate standard curves. Standards and patient sera were pipetted in duplicate at 50 microliters per well and mixed with 50 microliters of bead mixture. The microplate was incubated for 1 hour at room temperature on a microplate shaker. The wells were then washed three times with wash buffer using a vacuum manifold. Phycoerythrin (PE-) conjugated secondary antibodies were added to the appropriate wells and the wells were incubated in the dark for 45 minutes with constant shaking. The wells were washed twice, assay buffer was added to each well, and the samples were assayed using a Bio-Plex Suspension Array System (Bio-Rad Laboratories, Hercules, CA). Analysis of the experimental data was performed using a 5-parameter curve fitting. The results, expressed as the ratio of the concentration of a given antigen in the top phase to the concentration of a given antigen in the bottom phase (i.e., the partition coefficient), are presented in Table 10, which shows the difference between the solvent characteristics of the top phase and the bottom phase, and the partition coefficients for various antigens in serum. Table 9 shows the molecular properties of ATPS#5. [Table 9] [Table 10]
[0100] RANTES: selective attractant for memory T lymphocytes and monocytes; other abbreviations are provided in the table above.
[0101] The data presented in Table 8 show that the patterns of partition coefficients for the set of listed antigens are different between healthy controls and sera from patients with various cancers tested (breast, ovarian, pancreatic, and prostate cancer). These data are also different from the data presented in Tables 2, 4, 6, and 8 for ATPS#1, ATPS#2, ATPS#3, and ATPS#4, respectively. The patterns of individual biomarkers can be used to provide cancer specificity, or a set of biomarkers can be combined to derive a higher dimensional pattern with further enhanced specificity. Furthermore, combining partition information from at least two separate ATPSs and distinct molecular features for the same or separate biomarkers into one pattern can further enhance overall specificity.
[0102] Example 6 This example illustrates the determination of the specific molecular solvent properties used in Examples 1-5.
[0103] The solvatochromic probes 4-nitroanisole, 4-nitrophenol, and Reichardt's carboxylated betaine dye were used to measure the dipolarity / polarizability (π * ), hydrogen bond acceptor (HBA) basicity (β), and hydrogen bond donor (HBD) acidity (α) were measured.
[0104] One non-limiting exemplary procedure for determining these parameters is as follows. 1. Aqueous solutions (approximately 10 mM) of each solvatochromic dye were prepared, and 10 to 20 microliters of each was added separately to a given phase of a total volume of 500 microliters of ATPS. 2. A strong base was added to the samples containing Reichardt's carboxylated betaine dye (approximately 5 microliters of 1M NaOH to 500 microliters of a given phase) to ensure a basic pH. 3. To eliminate the charge transfer band of the phenolate anion observed in some solutions, strong acid was added to samples containing 4-nitrophenol (approximately 10 microliters of 1 M HCl to 500 microliters of that phase). 4. Each blank phase containing no dye was prepared separately. 5. The samples were homogenized in a vortex mixer and the absorption spectrum of each solution was measured. To ensure reproducibility and to avoid the effects of possible aggregation or other specific interactions, the position of the band maximum in each sample was measured in five separate aliquots. A UV-VIS microplate reader spectrophotometer SpectraMax Plus384 (Molecular Devices, Sunnyvale, CA, USA) with a bandwidth of 2.0 nm, data interval of 1 nm, and high-resolution scanning of approximately 0.5 nm / s acquired the UV-Vis molecular absorption data. The measured absorption spectra ranged from 240 nm to 600 nm. A baseline reference was established by scanning the black phase of ATPS without dye. The wavelength of the absorption maximum in each phase was determined and averaged using the PeakFit software package (Systat Software Inc., San Jose, CA, USA). The standard deviation for the measured maximum absorption wavelength was less than 0.4 nm for all dyes in all solutions examined.
[0105] The maximum shifts observed in the three solvents (water, n-hexane, and methanol) for various concentrations of 4-nitrophenol (with HCl) and 4-nitrophenol (without HCl) and Reichardt carboxylated betaine dye (with NaOH) and Reichardt carboxylated betaine dye (without NaOH) corresponded to literature values within experimental error.
[0106] Solvent dipolarity / polarizability π * To determine π * The value of is calculated from the wave number (ν1) of the longest wavelength absorption band of 4-nitroanisole dye according to the relationship: π * =0.427(34.12-ν1) was determined using
[0107] To determine the hydrogen bond acceptor basicity β of a solvent, the β value is calculated from the wavenumber (ν) of the longest wavelength absorption band of the 4-nitrophenol dye according to the relationship: β=0.346(35.045-ν2)-0.57π * was determined using
[0108] To determine the hydrogen bond donor acidity α of a solvent, the α value is calculated from the longest wavelength absorption band of Reichardt betaine dye according to the relationship: α=0.0649E T (30)-2.03-0.72π * was determined using That E T (30) was based on a solvatochromic pyridinium N -phenolate betaine dye (Reichardt dye) as a probe and its E T (30) is given by the wavelength (λ, nm) of the absorption band of its carboxylated form: E T (30)=(1 / 0.932)[(28591 / λ)-3.335] directly obtained as
[0109] The difference (c) between the electrostatic properties of the coexisting phases can be determined in each ATPS by partitioning a series of homologous sodium salts of dinitrophenylated (DNP) amino acids with aliphatic alkyl side chains of increasing length (alanine, norvaline, norleucine, and α-amino-n-octanoic acid). The logarithm of the partition coefficients of these compounds is multiplied by the number of equivalents of methylene groups, N c The N for the DNP-amino acids used was regressed against the side chain length in c The values are: DNP-alanine Na=1.31, DNP-norvaline Na=2.65, DNP-norleucine Na=3.75, and DNP-α-amino-n-octanoic acid Na=6.30. The regression equation is: log 10 K DNP-AA =c+E*N c In this formula, K DNP-AA is the partition coefficient of DNP-amino acid Na salt; N c is the number of equivalents of CH2 groups in the side chain, and E i and c i is a constant for a given ATPS system. This parameter can be used to determine the differences between the relative hydrophobicity and electrostatic properties of the phases.
[0110] Example 7 This example uses a parameter (e.g., Δπ * One protocol for determining Δα, Δβ, and c) is shown. These parameters generally measure the dipolarity / polarizability, hydrogen bond donor acidity, hydrogen bond acceptor basicity, and electrostatic properties of the solvent, respectively. This exemplary protocol generally relies on the following steps:
[0111] First, a coarse determination of chemical components for constructing suitable candidates for aqueous two-phase partitioning systems, which allows the selection of basic chemical components that generate aqueous two-phase partitioning systems with partition coefficients of the target protein biomarkers in the range of 0.1-10.
[0112] Such partition coefficients may allow practical compatibility with the final analytical assay. A very small initial partition coefficient or a very large initial partition coefficient may result in a significant proportion of clinical samples being outside the range of useful analytical detection, especially for low abundance protein biomarkers of interest that may be relevant for early cancer detection. For example, these may be at very low concentrations in circulating fluids such as blood.
[0113] In general, an aqueous two-phase partitioning system formed by two non-ionic polymers that results in a small difference between the overall solvent properties of the two phases is desirable. A system for efficient optimization of the chemical components in this process is one that uses components that differ in terms of their hydrophobic characteristics for hydrophobic proteins (e.g., PEG-Ucon). (商標) , Ucon (商標) - PVP, Ucon (商標) -PPG, PEG-PAG, PAG-PVP, PAG-PPG, etc.), and / or components for hydrophilic proteins, e.g., PEG-Ficoll®, PEG-PAM, PEG-PVP, PVP-PAM, etc.
[0114] Since aqueous two-phase systems composed of different starting chemical components can accommodate the same differences in their solvent properties, optimizing the partitioning behavior of the proteins of interest is not critical at this step: it may be sufficient to ensure that the range of their partitioning behavior lies within the acceptable analytical range.
[0115] Next, the solvent parameter Δπ *The aim of the present invention is to provide a crude mapping of the difference between two desired clinical conditions (e.g., cancer and benign phenotypes) in a general four-dimensional parameter space to determine the distribution landscape of the target protein using Δα, Δβ, and c. This is not prohibitive. The samples used are typically prepared by pooling about 20 or more individual samples corresponding to a particular disease phenotype. This provides an average representation of the genetically heterogeneous nature of the disease at the molecular level among individuals. Other information available about the individual target proteins may assist in the initial selection of the parameter space, for example, using protein isoelectric point to narrow the pH, etc. Generally, Design of Experiments (DOE) techniques may be used to map the parameter space. Examples of chemical additives that may be used to vary the solvent parameters include salts (which affect the difference between the electrostatic properties of the phases) and osmolytes (e.g., trimethylamine-N-oxide (TMAO), glucose, trehalose, arginine, lysine, etc.). Some additives (e.g., TMAO) can affect the solvent-solvent hydrogen bond donor acidity difference (Δα) and the solvent-solvent hydrogen bond acceptor basicity difference (Δβ), which can affect dipole-dipole interactions, the dipolarity / polarizability of water between coexisting phases (Δπ * ) only slightly. Other additives may also be used to modify these solvent parameters.
[0116] Once the partition landscape in the solvent parameter space is mapped, one or more optimization techniques can be used to determine the optimal point in the parameter space to achieve the degree of overall separation between those clinical phenotypes. Such techniques are known to those skilled in the art and include response surface methodology and various simple linear and nonlinear interpolation techniques. In some cases, more than one function can be optimized simultaneously. For example, maintaining the partition coefficients for both clinical phenotypes near 1 while maximizing the difference between their values can be one such dual objective function design to simultaneously achieve both analytical and clinical objectives. Also, the objective function that optimizes between multiple biomarkers instead of a single biomarker is computationally simple. For example, iterative directed optimization after initial sampling of the solvent parameter space can be used. This process does not require extensive experimentation, blind testing, or trial and error approaches.
[0117] The performance of the aqueous two-phase partitioning system identified with respect to its solvent properties can then be tested using two sample groups that represent the clinical phenotype of interest. This step typically involves a statistically significant number of samples (e.g., 50-100) from each type. The results are analyzed using conventional statistical techniques (e.g., receiver operating characteristic (ROC) analysis) to examine the trade-off between sensitivity and specificity. Further optimization can also be performed in this step.
[0118] This embodiment allows one to arrive at a set of solvent properties that underlie the partitioning behavior of a target protein. Differences between the partitioning behavior of the same protein that correspond to two different clinical phenotypes can be identified (e.g., different isoforms, etc.). In this embodiment, a general understanding of the role of various chemical components on the formation and modification of aqueous two-phase partitioning systems can be achieved without the need for exhaustive exploration of all possible polymer types, molecular weights, salts, additives, etc. Once an optimal composition is identified, for example using the above protocol, one or more sets of candidate chemical components for forming a system with those solvent properties can be easily identified. This can also allow the solvent properties to be measured, which can allow a set of aqueous two-phase partitioning systems to be pre-calibrated with respect to their solvent properties in order to build a "combinatorial library" for later use.
[0119] Although several embodiments of the present disclosure have been described and illustrated herein, various other means and / or structures for performing the functions and / or obtaining one or more of the results and / or advantages described herein will be readily envisioned by those skilled in the art, and each of such variations and / or modifications is deemed to be within the scope of the present invention. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described in this disclosure are intended to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the particular application(s) for which the teachings of the present invention are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the present disclosure described herein. Thus, it is to be understood that the above embodiments are presented by way of example only, and that within the scope of the appended claims and their equivalents, the present disclosure may be practiced otherwise than as specifically described and claimed. The present disclosure relates to each individual feature, system, article, material, kit, and / or method described herein. Furthermore, any combination of two or more such features, systems, articles, materials, kits, and / or methods is included within the scope of the disclosure, unless such features, systems, articles, materials, kits, and / or methods are mutually inconsistent.
[0120] In the event that the present specification and a document incorporated by reference include conflicting and / or inconsistent disclosure, the present specification shall control. In the event that two or more documents incorporated by reference include conflicting and / or inconsistent disclosure with respect to each other, the document having the later effective date shall control.
[0121] All definitions and those used herein should be understood to take precedence over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.
[0122] As used herein, the indefinite articles "a" and "an" should be understood to mean "at least one," unless the contrary is expressly stated in the specification and claims.
[0123] As used herein, the phrase "and / or" should be understood in the present specification and claims to mean "either or both" of the elements so conjoined, i.e., elements that are present conjunctively in some cases and disjunctively in other cases. Multiple elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" of the elements so conjoined. Other elements other than the elements specifically identified by the "and / or" clause may optionally be present, whether related or unrelated to the specifically identified elements. Thus, as a non-limiting example, a reference to "A and / or B," when used in conjunction with open-ended language such as "comprising," may refer in one embodiment to only A (optionally including elements other than B), in another embodiment to only B (optionally including elements other than A), and in yet another embodiment to both A and B (optionally including other elements), etc.
[0124] As used herein, in the specification and claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as being inclusive, i.e., including at least one of a number or recited elements, but also including more than one, and optionally including additional unrecited items. Only terms expressly stated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," refer to the inclusion of exactly one of a number or recited elements. In general, the term "or," when used herein, shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other, but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of."
[0125] As used herein, in the specification and claims, the phrase "at least one" in connection with one or more listed elements should be understood to mean at least one element selected from any one or more of the elements in the list, but not necessarily including at least one of each and every element specifically listed within the list of elements, nor excluding any combination of elements among the list of elements. This definition also allows that elements other than the elements specifically identified within the list of elements to which the phrase "at least one" refers may optionally be present, whether related or unrelated to the specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently, "at least one of A and / or B") can refer, in one embodiment, to at least one (optionally including more than one) A (and optionally including elements other than B) in the absence of B; in another embodiment, to at least one (optionally including more than one) B (and optionally including elements other than A) in the absence of A; in yet another embodiment, to at least one (optionally including more than one) A and at least one (optionally including more than one) B (and optionally including other elements), etc.
[0126] When the word "about" is used herein in connection with a number, it is to be understood that yet another embodiment of the present disclosure includes that number unmodified by the presence of the word "about."
[0127] Also, unless expressly stated to the contrary, in any method claimed herein that includes more than one step or act, it should be understood that the order of the method steps or acts is not necessarily limited to the order in which the method steps or acts are recited.
[0128] In the claims and the above specification, all transitional phrases such as "comprising," "including," "holding," "having," "containing," "involving," "possessing," "consisting of," and the like, are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as defined in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
Claims
1. A composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, The aqueous two-phase partitioning system comprises: (i) A difference in solvent dipolarity / polarizability (Δπ * ) where Δπ * is the dipolarity / polarizability (π * ) and the dipolarity / polarizability of the second phase (π * ), where π * is the wave number (ν 1 ) to cm -1 Measure in units of π in each phase * the difference in dipolarity / polarizability of the solvent, determined separately in each phase by calculating v = v as 0.427 (34.12-v); (ii) a difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of 0.001 + / - 0.035, Δα being determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, α being determined by measuring the maximum wavelength (λ) of the absorption band of carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932) [(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating (iii) a difference in solvent hydrogen bond acceptor basicity (Δβ) between the first phase and the second phase of −0.050+ / −0.021, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν 2 ) to cm -1 units, and β in each phase is 0.346 (35.045-ν 2 ) -0.57π * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between said first phase and said second phase of 0.020 + / - 0.135, c being determined by separately partitioning each dinitrophenylated amino acid sodium salt of Table I in said aqueous two-phase partitioning system, measuring the partition coefficient (K) of each sodium salt, and calculating the partition coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I; c ) to log 10 K = c + E c Electrostatic property differences, determined by regressing having Table I: 【Table 1-7】 The composition.
2. A composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, The aqueous two-phase partitioning system comprises: (i) The difference in solvent dipolarity / polarizability (Δπ) between the first phase and the second phase selected from a row in Table II. * ) where Δπ * is the dipolarity / polarizability (π * ) and the dipolarity / polarizability of the second phase (π * ), where π * is the wave number (ν 1 ) to cm -1 Measure in units of π in each phase * the difference in dipolarity / polarizability of the solvent, determined separately in each phase by calculating v = v as 0.427 (34.12-v); (ii) the difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase selected from the row in Table II, Δα being determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, α being determined by measuring the maximum wavelength (λ) of the absorption band of carboxylated pyridinium N-phenolate betaine in each phase in nm; the solvent polarity (E T (30)) was calculated as (1 / 0.932) [(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating (iii) the difference in hydrogen bond acceptor basicity (Δβ) of the solvent between the first phase and the second phase selected from the row in Table II, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν 2 ) to cm -1 units, and β in each phase is 0.346 (35.045-ν 2 ) -0.57π * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference (c) in electrostatic properties between said first phase and said second phase selected from said row in Table II, c being determined by separately partitioning each of the dinitrophenylated amino acid sodium salts of Table I in said aqueous two-phase partitioning system, measuring the partition coefficient (K) of each, and calculating the partition coefficient (K) and the methylene equivalent (N) of each of the dinitrophenylated amino acid sodium salts of Table I. c ) to log 10 K = c + E c Electrostatic property differences, determined by regressing having Table I shows 【Table 1-8】 and Table II 【Table 2-3】 The composition.
3. A composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, The aqueous two-phase partitioning system comprises: (i) The difference in solvent dipolarity / polarizability (Δπ) between the first phase and the second phase selected from a row in Table II. * ). (ii) the difference in hydrogen bond donor acidity of the solvent between the first phase and the second phase (Δα) selected from the row in Table II; (iii) the difference in solvent hydrogen bond acceptor basicity (Δβ) between the first phase and the second phase selected from the row in Table II; and (iv) the difference in electrostatic properties between the first phase and the second phase selected from the row in Table II (c) having Table II shows 【Table 2-4】 The composition.
4. providing at least a first aqueous multiphase partitioning system and a second aqueous multiphase partitioning system substantially identical in composition to the first partitioning system; determining a first cancer in a first subject by adding a first sample from a first cancer subject to the first partitioning system and determining the partitioning of a solute in the first sample within the first partitioning system; and determining a second cancer in a second subject by adding a second sample from a second cancer subject to the second partitioning system and determining the partitioning of the solute in the second sample within the second partitioning system. A method comprising:
5. 5. The method of claim 4, further comprising treating the first subject for the first cancer and treating the second subject for the second cancer.
6. 6. The method of claim 4 or 5, further comprising determining whether the first cancer and the second cancer are substantially the same.
7. The method of any one of claims 4 to 6, wherein the identity of the first cancer in the first subject is known.
8. 8. The method of claim 4, further comprising determining a partitioning of a second solute in the first sample in the first partitioning system, and determining a partitioning of the second solute in the second sample in the second partitioning system.
9. 9. The method of claim 4, further comprising determining a first partition coefficient for partition of the solute in the first sample in the first partition system, and determining a second partition coefficient for partition of the solute in the second sample in the second partition system.
10. 10. The method of claim 9, further comprising constructing a first signature comprising the first partition coefficient, and a second signature comprising the second coefficient.
11. The method of any one of claims 4 to 10, further comprising the step of comparing said first signature and said second signature to a signature obtained from a reference subject with a reference cancer.
12. The first cancer is selected from the group consisting of lymphoma, sarcoma and carcinoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, synovium, mesothelioma, lymphangioendothelial sarcoma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, and testicular tumor. Lung cancer, non-small cell lung cancer, small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma; leukemia, acute lymphocytic leukemia, acute myeloid leukemia, myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, erythroleukemia, chronic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, polycythemia vera, lymphoma, Hodgkin's disease, multiple myeloma, or Waldenstrom's macroglobulinemia, The method according to any one of claims 4 to 11, wherein the method is selected from the group consisting of
13. an aqueous multi-phase partitioning system exhibiting a first partition coefficient for a solute arising from a subject having a first cancer type, a second partition coefficient for the solute arising from a subject having a second cancer type, and a third partition coefficient for the solute arising from a subject having neither the first cancer type nor the second cancer type; A composition comprising:
14. A composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, The aqueous two-phase partitioning system comprises: (i) a difference in solvent dipolarity / polarizability (Δπ * ) where Δπ * is the dipolarity / polarizability (π * ) and the dipolarity / polarizability of the second phase (π * ), where π * is the wave number (ν 1 ) to cm -1 Measure in units of π in each phase * the difference in dipolarity / polarizability of the solvent, determined separately in each phase by calculating v = v as 0.427 (34.12-v); (ii) a difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of −0.380±0.095, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932) [(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating (iii) a difference in solvent hydrogen bond acceptor basicity (Δβ) between the first phase and the second phase of −0.020+ / −0.019, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν 2 ) to cm -1 units, and β in each phase is 0.346 (35.045-ν 2 ) -0.57π * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between said first phase and said second phase of 0.295 + / - 0.184, c being determined by separately distributing each dinitrophenylated amino acid sodium salt of Table I in said aqueous two-phase partitioning system, measuring the partition coefficient (K) of each sodium, and calculating the distribution coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I; c ) to log 10 K = c + E c Electrostatic property differences, determined by regressing having Table I shows 【Table 1-9】 The composition.
15. A composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, The aqueous two-phase partitioning system comprises: (i) a difference in solvent dipolarity / polarizability (Δπ * ) where Δπ * is the dipolarity / polarizability (π * ) and the dipolarity / polarizability of the second phase (π * ), where π * is the wave number (ν 1 ) to cm -1 Measure in units of π in each phase * the difference in dipolarity / polarizability of the solvent, determined separately in each phase by calculating v = v as 0.427 (34.12-v); (ii) a difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of −0.183±0.048, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932) [(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating (iii) a difference in solvent hydrogen bond acceptor basicity (Δβ) between the first phase and the second phase of 0.060+ / −0.020, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν 2 ) to cm -1 units, and β in each phase is 0.346 (35.045-ν 2 ) -0.57π * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between said first phase and said second phase of 0.575 + / - 0.125, c being determined by separately partitioning each dinitrophenylated amino acid sodium salt of Table I in said aqueous two-phase partitioning system, measuring the partition coefficient (K) of each sodium salt, and calculating the partition coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I; c ) to log 10 K = c + E c Electrostatic property differences, determined by regressing having Table I: 【Table 1-10】 The composition.
16. A composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, The aqueous two-phase partitioning system comprises: (i) −0.040±0.040 the difference in solvent dipolarity / polarizability between the first phase and the second phase (Δπ * ) where Δπ * is the dipolarity / polarizability (π * ) and the dipolarity / polarizability of the second phase (π * ), where π * is the wave number (ν 1 ) to cm -1 Measure in units of π in each phase * the difference in dipolarity / polarizability of the solvent, determined separately in each phase by calculating v = v as 0.427 (34.12-v); (ii) a difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of −0.270±0.052, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932) [(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating (iii) a difference in solvent hydrogen bond acceptor basicity (Δβ) between the first phase and the second phase of 0.021+ / -0.022, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν 2 ) to cm -1 units, and β in each phase is 0.346 (35.045-ν 2 ) -0.57π * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between said first phase and said second phase of 0.050+ / -0.060, c being determined by separately partitioning each dinitrophenylated amino acid sodium salt of Table I in said aqueous two-phase partitioning system, measuring the partition coefficient (K) of each sodium salt, and calculating the partition coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I; c ) to log 10 K = c + E c Electrostatic property differences, determined by regressing having Table I: 【Table 1-11】 The composition.
17. A composition comprising an aqueous two-phase partitioning system having a first phase and a second phase, The aqueous two-phase partitioning system comprises: (i) a difference in solvent dipolarity / polarizability (Δπ * ) where Δπ * is the dipolarity / polarizability (π * ) and the dipolarity / polarizability of the second phase (π * ), where π * is the wave number (ν 1 ) to cm -1 Measure in units of π in each phase * the difference in dipolarity / polarizability of the solvent, determined separately in each phase by calculating v = v as 0.427 (34.12-v); (ii) a difference in hydrogen bond donor acidity (Δα) of the solvent between the first phase and the second phase of −0.088±0.050, where Δα is determined as the difference between the hydrogen bond donor acidity (α) of the first phase and the hydrogen bond donor acidity (α) of the second phase, and α is determined by measuring the maximum wavelength (λ) of the absorption band of carboxylated pyridinium N-phenolate betaine in each phase in nm, the solvent polarity (E T (30)) was calculated as (1 / 0.932) [(28591 / λ)-3.335], and α in each phase was calculated as 0.0649E T (30)-2.03-0.72π * the difference in the hydrogen bond donor acidity of the solvent, determined separately in each phase by calculating (iii) a difference in solvent hydrogen bond acceptor basicity (Δβ) between the first phase and the second phase of 0.102 + / - 0.023, where Δβ is determined as the difference between the hydrogen bond acceptor basicity (β) of the first phase and the hydrogen bond acceptor basicity (β) of the second phase, and β is the wavenumber (ν 2 ) to cm -1 units, and β in each phase is 0.346 (35.045-ν 2 ) -0.57π * the difference in the hydrogen bond acceptor basicity of the solvent, determined separately in each phase by calculating (iv) a difference in electrostatic properties (c) between said first phase and said second phase of 0.775 + / - 0.125, c being determined by separately partitioning each dinitrophenylated amino acid sodium salt of Table I in said aqueous two-phase partitioning system, measuring the partition coefficient (K) of each sodium salt, and calculating the partition coefficient (K) and the methylene equivalent (N) of each sodium salt from Table I; c ) to log 10 K = c + E c Electrostatic property differences, determined by regressing having Table I: 【Table 1-12】 The composition.
Citation Information
Patent Citations
Characterization of molecules
US7968350B2
Systems and methods for characterization of molecules
US8099242B2
Characterization of molecules
US8211714B2
Systems and methods for characterization of molecules
US9354229B2
